

14th October 2019 | CannPal Animal Therapeutics Limited ACN: 612 791 518 | ASX:CP1

Release of securities from escrow

14th October 2019: Animal health company **CannPal Animal Therapeutics Limited (ASX:CP1)** ("CannPal" or "the Company") advises that in accordance with ASX Listing Rule 3.10A 49,990,405 fully paid ordinary shares will be released from escrow on October 25th 2019.

The Company also advises that 10,750,000 unquoted options and 1,875,000 unquoted performance rights will be released on October 25th 2019.

The Company will apply for quotation of these shares on October 25th 2019.

About CannPal Animal Therapeutics

CannPal Animal Therapeutics Limited (ASX: CP1) is a pharmaceutical-focused animal health Company researching the benefits of medical cannabis for companion animals. CannPal is researching and developing medicines derived from cannabinoids to provide veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.

CannPal has identified a significant opportunity to benefit from the rapidly growing medical cannabis and health markets by developing innovative therapeutics derived from the cannabis plant. The Company is working closely with regulatory authorities and veterinary research organisations conducting clinical trials to commercialise therapeutic products that will meet regulatory approval and support the health and well-being of companion animals. To learn more please visit: www.cannpal.com

ENDS

For further information, please contact:

CannPal

Layton Mills
Founder and Managing Director
M: +61 431 302 667
E: layton@cannpal.com

 @CannPalAT

 facebook.com/CannPal

